Scarica l'app Stockscreener
0.2642
3.65%
0.0093
Pre-mercato:
.26
-0.0042
-1.59%
Precedente Chiudi:
$0.2549
Aprire:
$0.267
Volume 24 ore:
653.01K
Relative Volume:
0.39
Capitalizzazione di mercato:
$25.80M
Reddito:
$27.47M
Utile/perdita netta:
$-26.60M
Rapporto P/E:
-0.843
EPS:
-0.3134
Flusso di cassa netto:
$-21.86M
1 W Prestazione:
-0.08%
1M Prestazione:
-6.71%
6M Prestazione:
-61.72%
1 anno Prestazione:
-73.48%
Intervallo 1D:
$0.25
$0.269
Intervallo di 1 settimana:
$0.2378
$0.2789
Portata 52W:
$0.2302
$1.05
Cue Biopharma Inc Stock (CUE) Company Profile
Nome
Cue Biopharma Inc
Settore
Industria
Telefono
617-949-2680
Indirizzo
40 GUEST STREET, BOSTON, MA
Compare CUE vs VRTX, REGN, ALNY, ARGX, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CUE
Cue Biopharma Inc
|
0.2642 | 25.80M | 27.47M | -26.60M | -21.86M | -0.3134 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Cue Biopharma Inc Stock (CUE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-03-13 | Iniziato | Jefferies | Buy |
| 2023-06-26 | Ripresa | Oppenheimer | Outperform |
| 2022-11-21 | Iniziato | Piper Sandler | Overweight |
| 2022-01-13 | Iniziato | H.C. Wainwright | Buy |
| 2022-01-03 | Iniziato | Craig Hallum | Buy |
| 2020-11-24 | Iniziato | Berenberg | Buy |
| 2020-04-09 | Iniziato | Stifel | Buy |
| 2020-01-28 | Iniziato | BTIG Research | Buy |
| 2020-01-22 | Iniziato | JMP Securities | Mkt Outperform |
Mostra tutto
Cue Biopharma Inc Borsa (CUE) Ultime notizie
Cue Biopharma Inc stock faces key test amid biotech volatility and pipeline progress - AD HOC NEWS
Cue Biopharma (CUE) Projected to Post Earnings on Monday - Defense World
Published on: 2026-03-21 13:01:47 - baoquankhu1.vn
Buyout Rumor: What chart patterns are forming on Cue Biopharma IncShare Buyback & Community Consensus Picks - baoquankhu1.vn
Certain Stock Incentive Plan of Cue Biopharma, Inc. are subject to a Lock-Up Agreement Ending on 20-MAR-2026. - marketscreener.com
Certain Common Stock of Cue Biopharma, Inc. are subject to a Lock-Up Agreement Ending on 20-MAR-2026. - marketscreener.com
Loss Report: Can Cue Biopharma Inc outperform in the next rallyIndex Update & Verified Momentum Stock Alerts - baoquankhu1.vn
Cue Biopharma (NASDAQ: CUE) files $300M shelf registration, $12.7M ATM via Jefferies - Stock Titan
Cue Biopharma 2024 Annual Report – Clinical-Stage Immunotherapy Pipeline, Regulatory Strategy, and Collaboration Highlights - Minichart
CUE SEC FilingsCue Biopharma Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Stock Report: Whats the RSI of Cue Biopharma Inc stockEarnings Growth Report & Smart Money Movement Alerts - baoquankhu1.vn
Cue Biopharma earnings beat by $0.10, revenue topped estimates - Investing.com Canada
Cue Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights - Bitget
Cue Biopharma issues quarterly and annual earnings update - Traders Union
Cue Biopharma : Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights - marketscreener.com
Reverse split on agenda as Cue Biopharma (CUE) plans 2026 virtual meeting - Stock Titan
Cue Biopharma, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Cue Biopharma (CUE) posts 2025 results and $15M ImmunoScape pact - Stock Titan
Cue Biopharma (CUE) pivots to autoimmune focus amid going concern risk - Stock Titan
Cue Biopharma, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Cue Biopharma (CUE) price target decreased by 20.00% to 4.08 - MSN
Published on: 2026-03-13 09:51:08 - baoquankhu1.vn
Cue Biopharma (CUE) Stock Analysis Report | Ratings, Financials & Performance - Benzinga Japan
Cue Biopharma to present new in vitro data for CUE-401 - TipRanks
Cue Biopharma (CUE) Unveils Promising CUE-401 Data at Global Con - GuruFocus
Cue Biopharma unveils in vitro data for CUE-401 in autoimmune disease research - Traders Union
Cue Biopharma to Present New In vitro Data for CUE-401 at the 20th World Immune Regulation Meeting (WIRM) 2026 - The Manila Times
Bull Run: Can Cue Biopharma Inc disrupt its industryWeekly Profit Recap & Expert Verified Stock Movement Alerts - baoquankhu1.vn
Cue Biopharma (NASDAQ: CUE) to vote on 1-for-30–1-for-50 reverse split - Stock Titan
CUE Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Update Recap: Can Cue Biopharma Inc disrupt its industryPortfolio Update Report & Fast Exit/Entry Strategy Plans - baoquankhu1.vn
Momentum Shift: Whats the MACD signal for OSR Holdings Inc Equity WarrantBull Run & Long-Term Safe Investment Ideas - baoquankhu1.vn
Stock Market Recap: Will Cue Biopharma Inc benefit from geopolitical trendsJuly 2025 Outlook & AI Powered Market Trend Analysis - baoquankhu1.vn
CUE Should I Buy - Intellectia AI
Cue Biopharma Sets 2026 Annual Meeting, Proposal Deadlines - TipRanks
Cue Biopharma sets April 13, 2026 annual meeting; February 28 deadline for shareholder proposals - TradingView
Cue’s CUE-401 well tolerated in mouse and NHP studies - BioWorld MedTech
Aug Technicals: Can Cue Biopharma Inc outperform in the next rallyJuly 2025 Levels & Free Safe Entry Trade Signal Reports - baoquankhu1.vn
Analyzing Cue Biopharma (NASDAQ:CUE) & Aardvark Therapeutics (NASDAQ:AARD) - Defense World
Autoimmune drug candidate CUE-401 passes early safety tests in animals - Stock Titan
Cue Biopharma Announces Preclinical Safety and Tolerability Data for CUE-401 for the Treatment of Autoimmune and Inflammatory Diseases - Bitget
Can Cue Biopharma Inc. outperform in the next rally2025 Earnings Surprises & Growth Focused Entry Point Reports - mfd.ru
Cue Biopharma Names Lucinda Warren Chief Financial Officer - The Globe and Mail
How Cue Biopharma Inc. stock performs in rising dollar environmentWeekly Gains Report & Daily Risk Controlled Trade Plans - mfd.ru
Cue Biopharma appoints industry veteran Lucinda Warren as chief financial and business officer - marketscreener.com
Cue Biopharma (CUE) Appoints New Chief Financial and Business Of - GuruFocus
Cue Biopharma, Inc. Appoints Lucinda Warren as Chief Financial Officer, Effective February 9, 2026 - marketscreener.com
Cue Biopharma Names Lucinda Warren Chief Financial And Business Officer - Nasdaq
Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Financial and Business Officer - Bitget
Cue Biopharma Appoints Lucinda Warren as Chief Financial and Business Officer - TradingView
Is Cue Biopharma Inc. stock attractive after correctionTreasury Yields & Short-Term High Return Ideas - mfd.ru
Cue Biopharma Inc Azioni (CUE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):